File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Primary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Index

TitlePrimary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Index
Authors
Issue Date2004
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2004, v. 103 n. 1, p. 216-221 How to Cite?
AbstractNasal natural killer (NK) cell lymphoma is rare, so that its optimal therapy, longterm outcome, and prognostic factors are unclear. Data on 52 men and 15 women with well-characterized nasal NK cell lymphomas were analyzed retrospectively to define the impact of primary therapy on remission and long-term outcome and the validity of the International Prognostic Index (IPI). Most (84%) had stage I/II disease with an IPI score of 1 or less (52%). Seven patients received radiotherapy only; 47 patients received anthracycline-containing chemotherapy plus consolidation radiotherapy; and 12 patients received nonanthracycline-containing chemotherapy plus radiotherapy. The overall complete remission (CR) rate was 64.2%; the 20-year overall survival (OS) and disease-free survival (DFS) rates were 37.1% and 33.5%, respectively. Front-line radiotherapy was apparently better than chemotherapy for CR (100% versus 59%, P= .04) and OS (83.3% versus 32.0%, P= .03). Relapses occurred in 4 radiotherapy-treated (all local) and 14 chemotherapy-treated patients (9 local, 4 systemic). Among these, 5 late relapses (4 local, 1 systemic) occurred at 170 months (range, 92-348 months) from CR. The IPI score was of prognostic significance for the whole group (IPI ≤ superior to IPI ≥ 2 for 20-year OS: 57.4% versus 27.6%, P = 0.012), as well as for patients treated with chemotherapy/radiotherapy (IPI ≤ 1 superior to IPI ≥ 2 for CR: 76.7% versus 35.7%, P = .017; and 10-year OS: 63.8% versus 26.8%, P = .003). © 2004 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/162748
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_US
dc.contributor.authorMa, SYen_US
dc.contributor.authorAu, WYen_US
dc.contributor.authorChoy, Cen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorYau, CCen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:23:04Z-
dc.date.available2012-09-05T05:23:04Z-
dc.date.issued2004en_US
dc.identifier.citationBlood, 2004, v. 103 n. 1, p. 216-221en_US
dc.identifier.issn0006-4971en_US
dc.identifier.urihttp://hdl.handle.net/10722/162748-
dc.description.abstractNasal natural killer (NK) cell lymphoma is rare, so that its optimal therapy, longterm outcome, and prognostic factors are unclear. Data on 52 men and 15 women with well-characterized nasal NK cell lymphomas were analyzed retrospectively to define the impact of primary therapy on remission and long-term outcome and the validity of the International Prognostic Index (IPI). Most (84%) had stage I/II disease with an IPI score of 1 or less (52%). Seven patients received radiotherapy only; 47 patients received anthracycline-containing chemotherapy plus consolidation radiotherapy; and 12 patients received nonanthracycline-containing chemotherapy plus radiotherapy. The overall complete remission (CR) rate was 64.2%; the 20-year overall survival (OS) and disease-free survival (DFS) rates were 37.1% and 33.5%, respectively. Front-line radiotherapy was apparently better than chemotherapy for CR (100% versus 59%, P= .04) and OS (83.3% versus 32.0%, P= .03). Relapses occurred in 4 radiotherapy-treated (all local) and 14 chemotherapy-treated patients (9 local, 4 systemic). Among these, 5 late relapses (4 local, 1 systemic) occurred at 170 months (range, 92-348 months) from CR. The IPI score was of prognostic significance for the whole group (IPI ≤ superior to IPI ≥ 2 for 20-year OS: 57.4% versus 27.6%, P = 0.012), as well as for patients treated with chemotherapy/radiotherapy (IPI ≤ 1 superior to IPI ≥ 2 for CR: 76.7% versus 35.7%, P = .017; and 10-year OS: 63.8% versus 26.8%, P = .003). © 2004 by The American Society of Hematology.en_US
dc.languageengen_US
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/en_US
dc.relation.ispartofBlooden_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshCombined Modality Therapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshKiller Cells, Naturalen_US
dc.subject.meshLymphoma - Drug Therapy - Radiotherapy - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNasal Cavityen_US
dc.subject.meshNose Neoplasms - Drug Therapy - Radiotherapy - Therapyen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshSalvage Therapyen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titlePrimary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Indexen_US
dc.typeArticleen_US
dc.identifier.emailChim, CS:jcschim@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityChim, CS=rp00408en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1182/blood-2003-05-1401en_US
dc.identifier.pmid12933580en_US
dc.identifier.scopuseid_2-s2.0-0347597762en_US
dc.identifier.hkuros87664-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0347597762&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume103en_US
dc.identifier.issue1en_US
dc.identifier.spage216en_US
dc.identifier.epage221en_US
dc.identifier.isiWOS:000187573000041-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChim, CS=7004597253en_US
dc.identifier.scopusauthoridMa, SY=7403725725en_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridChoy, C=7202840937en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridYau, CC=7007038422en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats